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Abstract: BACKGROUND The Post-Pulmonary Embolism Syndrome (PPES) comprises heterogeneous
entities, including chronic thromboembolic disease with/without pulmonary hypertension (CTEPH/CTEPD),
and deconditioning. OBJECTIVES To assess underlying physiological determinants of PPES, and ef-
ficacy and safety of rehabilitation training in these patients. METHODS 56 consecutive PE patients
with persistent dyspnea and/or functional limitations despite ฀3 months of anticoagulation underwent
standardized diagnostic work-up including exercise testing as part of routine practice. All diagnostic
(imaging and cardiopulmonary function) tests were interpreted by a core group of experienced clinicians.
A subgroup of patients without CTEPH or other treatable conditions was referred for a 12-week per-
sonalized rehabilitation program, studying changes in physical condition and patient-reported outcome
measures. RESULTS Persistent vascular occlusions were observed in 21/56 patients (38%) and CTEPH
was confirmed in ten (18%). Regarding those without CTEPH, impaired cardiopulmonary responses were
evident in 18/39 patients with available CPET data (46%), unrelated to chronic thrombi. Rehabilita-
tion was completed by 27 patients after excluding 29 (patients with CTEPH or treatable comorbidities,
refusal, ineligibility, or training elsewhere). Training intensity, PE-specific quality of life (PEmb-QoL)
and fatigue (CIS) improved with a median difference of 20 W (p = 0.001), 3.9 points (p < 0.001) and
16 points (p = 0.003), respectively. Functional status (Post-VTE Functional Status Scale) improved
฀1 grade in 18 (67%) patients, and declined in one (3.7%). CONCLUSIONS Our findings suggest that
abnormal cardiopulmonary responses to exercise are common in patients with PPES and are not limited
to those with chronic thrombi. Offering pulmonary rehabilitation to patients not treated otherwise seems
safe and promising.
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Quality of life 
A B S T R A C T   
Background: The Post-Pulmonary Embolism Syndrome (PPES) comprises heterogeneous entities, including 
chronic thromboembolic disease with/without pulmonary hypertension (CTEPH/CTEPD), and deconditioning. 
Objectives: To assess underlying physiological determinants of PPES, and efficacy and safety of rehabilitation 
training in these patients. 
Methods: 56 consecutive PE patients with persistent dyspnea and/or functional limitations despite ≥3 months of 
anticoagulation underwent standardized diagnostic work-up including exercise testing as part of routine practice. 
All diagnostic (imaging and cardiopulmonary function) tests were interpreted by a core group of experienced 
clinicians. A subgroup of patients without CTEPH or other treatable conditions was referred for a 12-week 
personalized rehabilitation program, studying changes in physical condition and patient-reported outcome 
measures. 
Results: Persistent vascular occlusions were observed in 21/56 patients (38%) and CTEPH was confirmed in ten 
(18%). Regarding those without CTEPH, impaired cardiopulmonary responses were evident in 18/39 patients 
with available CPET data (46%), unrelated to chronic thrombi. Rehabilitation was completed by 27 patients after 
excluding 29 (patients with CTEPH or treatable comorbidities, refusal, ineligibility, or training elsewhere). 
Training intensity, PE-specific quality of life (PEmb-QoL) and fatigue (CIS) improved with a median difference of 
20 W (p = 0.001), 3.9 points (p < 0.001) and 16 points (p = 0.003), respectively. Functional status (Post-VTE 
Functional Status Scale) improved ≥1 grade in 18 (67%) patients, and declined in one (3.7%). 
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Conclusions: Our findings suggest that abnormal cardiopulmonary responses to exercise are common in patients 
with PPES and are not limited to those with chronic thrombi. Offering pulmonary rehabilitation to patients not 
treated otherwise seems safe and promising.   
1. Introduction 
After acute pulmonary embolism (PE), up to half of patients report 
persistent dyspnea and/or functional limitations despite adequate 
anticoagulant treatment [1–6]. The so-called Post-PE Syndrome (PPES) 
is characterized by a combination of abnormalities in echocardiographic 
parameters of right ventricular function, pulmonary artery hemody-
namics and impaired gas exchange with increased dead-space ventila-
tion at rest or during exercise, all possibly caused by the persistent 
thrombotic obstruction of the pulmonary arteries [7–11]. The most se-
vere presentation of PPES is chronic thromboembolic pulmonary hy-
pertension (CTEPH), with a 2–4% incidence among PE survivors [12]. 
Even if pulmonary artery pressures at rest are normal in the presence of 
persistent perfusion defects, a relatively high pulmonary vascular 
resistance, reduced right ventricular contractile reserve and increased 
dead-space ventilation may account for debilitating exertional dyspnea, 
also referred to as chronic thromboembolic pulmonary disease (CTEPD) 
[13–16]. Etiologies explaining persistent complaints in patients without 
persistent perfusion defects include chronic right ventricular impair-
ment, deconditioning and/or pre-existing comorbidities [5,17–20]. 
Depressive disorders, fear for potential complications or recurrences, 
and post-thrombotic panic syndrome further contribute to long-term 
functional impairment, which may lead to physical inactivity, subse-
quent deconditioning and a downward spiral as result [21,22]. Alto-
gether, PPES is associated with decreased quality of life, unemployment 
and increased utilization of healthcare resources, although the under-
lying physiological determinants are largely unknown [19,23,24]. 
Curative treatment for CTEPH is available, preferably pulmonary 
endarterectomy (PEA), whereas the optimal management of other forms 
of the PPES is not well established [25]. Small studies have shown 
promising results of PEA or balloon pulmonary angiography (BPA) in 
patients with CTEPD, but this is currently not the standard of care 
[26–29]. Although only few experience is available for pulmonary 
rehabilitation in patients with PPES, small studies do suggest positive 
effects on exercise capacity and quality of life in both PE patients 
[30–35] and those with CTEPH [36–40]. In the setting of other acute and 
chronic cardiopulmonary conditions e.g. coronary heart disease, chronic 
obstructive pulmonary disease (COPD), and interstitial lung disease, 
cardiac and/or pulmonary rehabilitation programs are routinely offered 
because of established reduction of cardiovascular mortality and 
morbidity, as well as improvement in quality of life, symptoms and 
exercise capacity [41,42]. We hypothesized that a personalized reha-
bilitation program may also improve functional status in patients with 
PPES. 
In this study, we studied the underlying determinants of persistent 
complaints in patients with PPES, and aimed to get insight into the ef-
ficacy and safety of an outpatient pulmonary rehabilitation program in 
patients with PPES in whom CTEPH and CTEPD suitable for PEA or BPA 
were ruled out. 
2. Methods 
2.1. Study design and patients 
This observational cohort study is a description of routine care. We 
prospectively followed all consecutive patients with imaging-confirmed 
acute PE [43,44] referred to the ‘post-PE syndrome clinic’ of the Leiden 
University Medical Center (LUMC) between May 2017 and May 2019 
[45]. Firstly, in this dedicated clinic, adult PE patients with persistent 
moderate-to-severe dyspnea (modified Borg scale ≥3 at rest) and/or 
patient-reported relevant functional limitations despite adequate anti-
coagulation for at least 3 months were subjected to a standardized 
diagnostic work-up. Secondly, a subgroup of these patients that were not 
subjected to specific CTEPH/CTEPD treatment and did not have un-
derlying comorbidities explaining their persistent symptoms, were 
invited to follow a post-PE-specific pulmonary rehabilitation program in 
an expertise center for specialist medical rehabilitation care (Basalt, 
Leiden, the Netherlands). 
The local Ethics Committees of both LUMC and Basalt waived the 
need for informed consent because of the observational design of this 
study. All patients were actively informed of the intention to use the 
results and outcome of the dedicated clinic for scientific purposes and 
we have explicitly offered all patients to opt out. None objected to the 
use of anonymized data. 
2.2. Objectives 
The primary objectives of this study were: 1) to evaluate the un-
derlying physiological determinants of exertional dyspnea in all patients 
referred to our ‘post-PE syndrome clinic’; and 2) to get insight in the 
safety and efficacy of a rehabilitation program on training intensity, and 
patient-reported outcome measures in a subgroup of patients in whom 
CTEPH and CTEPD suitable for PEA or BPA were ruled out after stan-
dardized diagnostic work-up. 
2.3. Procedures 
2.3.1. Diagnostic work-up 
This includes routine blood testing, resting echocardiography, 
computed tomography pulmonary angiography (CTPA) with subtrac-
tion perfusion mapping, cardiopulmonary exercise test using a station-
ary cycle ergometer (CPET), and pulmonary function test, if relevant 
followed by invasive right heart catheterization (RHC), ventilation/ 
perfusion imaging and/or pulmonary angiography [46]. The baseline 
test results were discussed in a multidisciplinary team of pulmonary 
hypertension experts, including cardiologists, pulmonologists, rheuma-
tologists and vascular medicine specialists. Patients with (suspected) 
CTEPH or CTEPD potentially suitable for PEA or BPA were referred to 
the VU University Medical Center (CTEPH expertise center) for appro-
priate treatment. CTEPH was established if the following strict diag-
nostic criteria were met: 1) ≥1 mismatched segmental perfusion defect 
demonstrated by ventilation/perfusion (V/Q) scanning after ≥3 months 
of adequate therapeutic anticoagulation; 2) mean pulmonary artery 
pressure (mPAP) ≥25 mm Hg at rest measured by RHC; and 3) pulmo-
nary artery wedge pressure (PAWP) ≤15 mm Hg [46]. In case a treatable 
comorbidity was found, e.g. asthma, interstitial lung disease or left heart 
failure, treatment optimization was provided by the relevant medical 
specialist of the multidisciplinary team. 
2.3.2. Rehabilitation program 
The 12-week outpatient rehabilitation program in the previously 
mentioned subgroup was based on the Official ATS/ERS Statement: Key 
Concepts and Advances in Pulmonary Rehabilitation [42]. Patients 
participated in twice-weekly sessions of 90 min of supervised exercise 
training and, after two weeks, supplemented with one unsupervised 
training at home (Appendix A). During the supervised sessions, patients 
performed 30 to 40 min of endurance exercise, and 30 min of strength 
exercises. The endurance training was performed on a stationary cycle 
ergometer and/or a treadmill, and comprised endurance and/or interval 
exercise. According to current guidelines, each training was targeted at 
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70 to 80% of patients' individual maximum heart rate, which was 
routinely checked by the physiotherapist supervising the training 
[42,47]. When patients were over- or underperforming, if tolerable, this 
was corrected by adjusting the workload of the training in order to ac-
quire the targeted heart rate. Strength training was aimed at either 
improving absolute muscle strength or improvement in muscle endur-
ance using medical fitness equipment. For improvement of strength, 
patients trained at 75% of their one repetition maximum (1RM), per-
forming 3 series of 8 repetitions. When training muscle endurance, 2 
series of 15 repetitions at 65% of the 1RM were performed. Concerning 
the third training each week performed at home, patients were 
instructed to reach the same intensity as they did in the supervised 
training sessions. Additional counselling was tailored to the individual 
patient's needs and included support by a psychologist, dietician, 
occupational therapist or social worker including smoking cessation 
counselling if relevant (Appendix A). 
2.4. Measurements 
2.4.1. Diagnostic work-up 
An incremental symptom-limited CPET was performed, if possible 
along with arterial blood sampling. Individual CPET results were used to 
evaluate cardiopulmonary responses to exercise in PPES according to 
the ATS/ACCP Statement and Wasserman's algorithms, particularly 
concerning presence of respiratory gas exchange, ventilatory efficiency 
and abnormal dead-space ventilation. Typical patterns of impaired (i.e. 
insufficient) cardiopulmonary responses to exercise are shown in 
Table 1 [48,49]. Evaluation of results was done by 2 independent re-
searchers (GJAMB and MKN). Parameters collected throughout the test 
include: oxygen uptake (VO2), heart rate (HR), minute ventilation (VE), 
O2 pulse (VO2/HR), anaerobic threshold (AT, determined using the V- 
slope method), carbon dioxide production (VCO2), arterial oxygen 
saturation, ventilatory equivalents for carbon dioxide (VE/VCO2, point 
measure at AT), dead-space fraction (Vd/Vt), alveolar-arterial gradient 
(p(A-a)O2). Since maximum voluntary ventilation (MVV) was not 
directly measured, it was calculated using the following prediction 
equation (FEV1 × 40) [50]. All parameters were obtained during peak 
exercise except for AT and VE/VCO2 at AT, reference values from the 
ATS-ACCP Statement on CPET were used [49]. 
Pulmonary function testing comprised spirometry, body plethys-
mography, and single breath carbon monoxide diffusion [53]. Echo-
cardiographic explanations of persistent dyspnea were classified as signs 
of pulmonary hypertension, signs of diastolic or systolic dysfunction, 
valvular heart disease, and/or cardiomyopathy. CTPA with iodine 
perfusion mapping was performed to assess the presence of residual 
thrombotic lesions and/or persistent perfusion defects on CT scanners 
with at least 64 slices and a reconstructed slice thickness of 1 to 3 mm. 
2.4.2. Rehabilitation program 
Training intensity (defined as peak power output in W) was used as a 
surrogate for measuring the effect of rehabilitation since maximal 
workload as determined by CPET was not available at discharge. Peak 
power output was assessed during the first and last training sessions of 
the rehabilitation program. Questionnaires on self-reported quality of 
life (PEmb-QoL, PE-specific Quality of Life), fatigue (CIS, Checklist In-
dividual Strength-Fatigue), and anxiety and depression (HADS, Hospital 
Anxiety and Depression Scale) were completed before start and after 
completion of the rehabilitation program [54–57]. Two independent 
researchers (SMJJ and GJAMB) evaluated functional status before and 
after the rehabilitation program for each participant and assigned a 
grade on the Post-VTE Functional Status (PVFS) Scale (Appendix B) 
[58–60]. Subsequently, the degree of improvement or decline was 
evaluated, both at group and at individual level. Safety issues were 
closely monitored and reported 1) during a specific training session (i.e. 
syncope or arrhythmia); or 2) while completing the rehabilitation pro-
gram (i.e. symptomatic recurrent venous thromboembolism, new car-
diopulmonary diagnoses, death). Data on relevant patient 
demographics, the PE diagnosis, comorbidities, relevant outpatient 
follow-up details, results of the standardized diagnostic testing and de-
tails of the rehabilitation program were extracted from the medical 
charts by the treating physician. 
2.5. Statistical analysis 
Baseline characteristics are described as mean with standard devia-
tion (SD), median with interquartile range (IQR), or numbers with 
proportions if appropriate. Comparison of variables before start and 
after completing the rehabilitation program was performed using the 
paired t-test or Wilcoxon matched-pairs signed rank test where appro-
priate. Measures of odds ratio (OR) are reported as point estimates with 
corresponding 95% confidence intervals (95% CI). All statistical tests 
were performed using SPSS Statistics software (version 25.0, IBM) and 
visualisation was conducted using SankeyMATIC (http://sankeymatic. 
com/build/). Validated minimal clinically important differences 
(MCIDs) of the individual tests and questionnaires have been used if 
available to determine relevant outcomes when comparing results 
before and after completing the rehabilitation program [61,62]. 
3. Results 
3.1. Baseline 
The baseline characteristics of 56 patients referred to the ‘post-PE 
syndrome clinic’ after adequate anticoagulant treatment are displayed 
in Table 2, all of whom underwent standardized diagnostic work-up 
(Fig. 1). Of the total study population, cardiopulmonary responses 
were evaluated in 45 patients after excluding those with alternative 
diagnoses (N = 3) and those whom refused to undergo a CPET (N = 8). A 
total of 27 patients participated in the PE-specific rehabilitation pro-
gram after the exclusion of 29 patients (CTEPH, N = 10; alternative 
diagnoses, N = 3; ineligibility to participate, N = 3; or lack of motiva-
tion, N = 6). Rehabilitation was performed elsewhere because of patient 
Table 1 
Typical patterns of insufficient cardiopulmonary responses to exercise, useful for 







Peak VO2 Reduced Reduced Reduced 





Reduced/plateau Normal Reduced/plateau 
Peak SpO2 Normal/drop Normal/drop Drop 
VE/MVV Normal Increased Normal 
VE/VCO2 
at AT 
Increased Increased Increased 
Vd/Vt Increased Increased Increased 
P(A-a)O2 Normal/increased Increased Increased 
Note: adapted from references [48,49,51,52]. Maximum or peak cardiopulmo-
nary responses except for VE/VCO2 at AT. 
Abbreviations: CPET, cardiopulmonary exercise testing; VO2, oxygen uptake, 
pred, predicted; HR, heart rate; O2 pulse, oxygen consumed per heart rate; 
SpO2, arterial oxygen saturation; VE/MVV, ventilatory reserve; VE/VCO2, 
ventilatory equivalent for carbon dioxide; AT, anaerobic threshold; Vd/VT, 
dead-space fraction; p(A-a)O2, alveolar-arterial gradient; V/Q, ventilation/ 
perfusion; Y, yes; CTEPH, chronic thromboembolic pulmonary hypertension. 
a Cardiovascular impairment refers to left ventricular failure, congestive heart 
disease and myocardial ischemia. 
b Respiratory impairment refers to parenchymal disease including obstructive 
and restrictive lung diseases and lung disease with impaired peripheral 
oxygenation. 
c Pulmonary vascular impairment refers to diseases with increased dead-space 
ventilation. 
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preferences in 7 patients. 
3.2. Diagnostic work-up 
Median time from PE diagnosis till referral was 6.4 months (IQR 
4.3–31). A total of 16 of 56 (29%) patients had at least one pre-existing 
comorbidity, including 10 patients (18%) having COPD/asthma and 3 
(5.4%) having diabetes mellitus. After completing standardized diag-
nostic work-up in the total population, CTEPH was confirmed by right 
heart catheterization (RHC) in ten patients (18%). Median time between 
PE and CTEPH diagnosis was 4.5 months (IQR 3.0–11). Echocardiog-
raphy revealed signs of PH in three other patients, whom had no PH at 
invasive measurement by RHC, and diastolic dysfunction was observed 
in two. In addition to CTEPH patients, unresolved thrombi (according to 
CTPA assessment) and/or persistent perfusion defects (based on V/Q 
scan) were present in 21 patients (38%), none of whom were treated 
with PEA or BPA. Of the remaining 25 patients, previously unknown 
conditions were considered to be the primary etiology of the persistent 
dyspnea in three (5%) patients: iron deficiency anemia in one and 
interstitial lung disease in two patients. 
3.3. Exercise-induced cardiopulmonary response evaluation 
During peak exercise, CPET revealed a median power output of 120 
W (IQR 80 to 180) with a mean heart rate of 146/min (SD 24) and a 
median breathing frequency of 35/min (IQR 31 to 43) (Table 3). Mean 
peak VO2 was 1683 (SD 785) ml/min and was reduced (<85% of pre-
dicted) in 19 of 45 patients (42%). Mean minute ventilation at peak 
exercise consisted of 71 L/min (SD 27), which is 61% of MVV (SD 0.16). 
Unresolved thrombi and/or persistent perfusion defects were present in 
24 of 45 patients (53%) including 6 with CTEPH. Of 39 non-CTEPH 
cases, either pulmonary vascular or cardiovascular impairment was 
observed during incremental exercise in 21 (54%) patients, of whom 11 
(52%) had residual vascular occlusions (odds ratio 1.7, 95%CI 0.48 to 
6.2). Pulmonary vascular impairment was the exclusive underlying 
determinant in six (15%) patients and cardiovascular impairment in one 
(2.6%). All CTEPH patients had either signs of pulmonary vascular or 
cardiovascular impairment. Parenchymal lung disease was ruled out as 
Table 2 
Baseline characteristics of the patients with Post-PE Syndrome subjected to the 
standardized diagnostic work-up.   
All PE patients (N = 56) 
Age at PE event (years, mean ± SD) 54 (14) 
Male sex (N, %) 22 (39%) 
BMI (kg/m2, mean ± SD) 29 (6.3) 
Located in main pulmonary artery 14 (25%) 
Unprovoked PE (N, %) 29 (52%) 
Previous VTE (N, %) 15 (27%) 
Pre-existing comorbidity (N, %)  
COPD/asthma 10 (18%) 
Diabetes mellitus 3 (5.4%) 
Coronary artery disease 2 (3.6%) 
Heart failure 2 (3.6%) 
Active malignancy 1 (1.8%) 
Smoking status (N, %)  
Never 30 (54%) 
Quit smoking 19 (34%) 
Pack years (mean ± SD): 16 (11) 
Currently smoking 7 (13%) 
Pack years (mean ± SD): 35 (18) 
Type of anticoagulant treatment (N, %)  
DOAC 27 (48%) 
VKA 26 (46%) 
LMWH 2 (3.6%) 
Indefinite anticoagulant treatment (N, %) 34 (61%) 
Abbreviations: PE, pulmonary embolism; SD, standard deviation; BMI, body 
mass index; VTE, venous thromboembolism; COPD, chronic obstructive pul-
monary disease; LMWH, low-molecular-weight heparin; VKA, vitamin K 
antagonist; DOAC, direct oral anticoagulant. 
Pulmonary vascular and / or 









- Alternative diagnoses (N=3)
- Ineligibility/lack of motivation (N=9)









All patients with PPES (N=56)






Fig. 1. Flowchart of study patients highlighting both stages of the study: 1) Diagnostic work-up with CTPA and echocardiography was performed in all patients, but 
CPET allowing cardiopulmonary response evaluation data was only available for 45 patients. The presence/absence of CTEPH and the presence/absence of persistent 
vascular occlusions are shown, with corresponding CPET findings. 2) The rehabilitation program was completed by 27 patients. 
Abbreviations: PPES, Post-PE Syndrome; CPET, cardiopulmonary exercise test; CTEPH, chronic thromboembolic pulmonary hypertension. 
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Table 3 






























35  68  52  93  47%    Y: CTEPH Cardiovascular impairment 
No. 
2  








65  73  89  94  55% 33,5   Y: CTEPH Cardiovascular impairment 
No. 
5  
90  98  92  89  54% 38,3  42 6,65 Y: CTEPH Pulmonary vascular impairment 
No. 
6  




62  86  72  95  72%    Y Cardiovascular impairment 
No. 
8  




115  89  128  99  65% 24,8  14 3,38 Y No cardiovascular, respiratory or 
pulmonary vascular impairment 
No. 
10  
99  103  96  95  68% 33,8  5,54 Y Pulmonary vascular impairment 
No. 
11  
129  93  136  95  67% 27   Y No cardiovascular, respiratory or 
pulmonary vascular impairment 
No. 
12  
93  100  101   94% 48,2  23  Y Pulmonary vascular impairment 
(combined with a component 
interstitial lung disease) 
No. 
13  
78  80  98  99  44% 25,4   Y Cardiovascular impairment 
No. 
14  




93  101  92  97  80% 33,5  18 4,22 Y No cardiovascular, respiratory or 
pulmonary vascular impairment 
No. 
16  
101  103  98  98  73% 29,2   Y No cardiovascular, respiratory or 
pulmonary vascular impairment 
No. 
17  
101  98  104  99  54%   28 4,1 Y Pulmonary vascular impairment 
No. 
18  




97  99  95  99  72% 26,6   Y No cardiovascular, respiratory or 
pulmonary vascular impairment 
No. 
20  




97  109  87  91  85% 32,7   Y No cardiovascular, respiratory or 
pulmonary vascular impairment 
No. 
22  
101  77  131  99  61% 27,1   Y No cardiovascular, respiratory or 
pulmonary vascular impairment 
No. 
23  
96  84  114  96  64% 37  30 5,93 Y Pulmonary vascular impairment 
No. 
24  
62   82      Y Cardiovascular impairment 
No. 
25  
117  89  132  97  50% 25,4  15 2,12 – No cardiovascular, respiratory or 
pulmonary vascular impairment 
No. 
26  
95  94  101  100  72% 24,8  25  – No cardiovascular, respiratory or 
pulmonary vascular impairment 
No. 
27  
119  73  178  99  29,9   – No cardiovascular, respiratory or 
pulmonary vascular impairment 
No. 
28  
83  94  74  100  27,8   – Cardiovascular impairmentc 
No. 
29  
95  78  121  100  53% 31,7   – No cardiovascular, respiratory or 
pulmonary vascular impairment 
No. 
30  
103  79  131  99  62% 29,5  23 3,1 – No cardiovascular, respiratory or 
pulmonary vascular impairment 
No. 
31  
85  70  120  100  53% 34,4   – No cardiovascular, respiratory or 
pulmonary vascular impairment 
No. 
32  
89  97  91  98  107% 35,4  31 2,79 – Pulmonary vascular impairmentc 








105  106  99  97  42% 28,7  3,82 – No cardiovascular, respiratory or 
pulmonary vascular impairment 
No. 
35  
85  97  89  99  49% 31,1   – No cardiovascular, respiratory or 
pulmonary vascular impairment 
(continued on next page) 
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primary etiology in any of these study patients. Mild respiratory 
impairment, however, contributed partially in two patients, i.e. asthma 
and interstitial lung disease (Table 3). 
3.4. Rehabilitation program 
Our personalized 12-week rehabilitation program was completed by 
27 patients, of whom 17 were female (63%) and mean age was 51 years 
(SD 14). At baseline, PEmb-QoL score was median 15 points (IQR 12 to 
17) whereas the median CIS score was above the cut-off value for 
problematic fatigue (≥76): 93 (IQR 76 to 104) [63]. HADS anxiety and 
depression scores exceeded the cut-off value of ≥8.0 points in three and 
four patients, respectively, indicating a possible anxiety or depressive 
disorder before start of the rehabilitation program. Median score for 
anxiety was 4.0 points (IQR 2.0 to 7.0), and for depression 6.0 points 
(IQR 3.0 to 8.0). Supervised training sessions were provided twice a 
week in 23 participants, and three times a week in 4 participants since 
full supervision in exercise training was required in these patients. 
Additional counselling was provided by a social worker in 24 (89%), a 
dietician in 19 (70%), occupational therapist in 17 (63%), and a psy-
chologist in 15 (56%) patients. Two patients underwent smoking 
cessation counselling (7.4%), of whom one quitted smoking. 
The duration of the rehabilitation program was median 13 weeks 
(IQR 11 to 16). Peak power output during the first versus the last 
training session was median 65 W (IQR 40 to 90) versus 75 W (IQR 40 to 
135) with a median difference of 20 W (IQR 5.0 to 40; p = 0.001). 
Quality of life was improved after rehabilitation with a median differ-
ence of 3.9 points (IQR −6.2 to −1.2; p < 0.001) on the PEmb-Qol total 
score (Table 4). Changes in individual dimensions of the Pemb-QoL 
questionnaire are displayed in Fig. 2. The burden of fatigue decreased 
with a median difference of 16 points on the CIS score (−39 to −3.5; p =
0.003), reflecting statistically relevant improvement. Lower burden on 
both anxiety and depression domains of the HADS were reported (me-
dian difference 1.0 point, IQR −2.0 to 1.0 for each) with no improve-
ment (p = 0.19 and p = 0.096), respectively (Table 4). 
Moderate or severe functional limitations (PVFS scale grade ≥3) 
were present in 18 of 27 (67%) patients before rehabilitation, and in 7/ 
27 (26%) at post-rehabilitation assessment, which is reflected by an 
overall improvement on the PVFS scale (p < 0.001; Fig. 3). Fourteen 
patients (52%) improved one grade on the PVFS scale and four patients 
(15%) improved two grades. Functional status remained unchanged in 8 
patients (30%), whereas the remaining patient had a decline of one 






























74  70  107  96  28% 27,5   – Cardiovascular impairmentc 
No. 
37  
88  96  135      – No cardiovascular, respiratory or 
pulmonary vascular impairment 
No. 
38  
77  86  90  100  58% 31,5   – Cardiovascular impairmentc 
No. 
39  
77  77  100  100  46% 25  6 1,85 – Cardiovascular impairmentc 
No. 
40  
81  74  110  100  33% 29,5   – Cardiovascular impairmentc 
No. 
41  
104  98  106  98  69% 26,6  17 3,77 – No cardiovascular, respiratory or 
pulmonary vascular impairment 
No. 
42  
95  80  118  96  61% 35  19 3,04 – Pulmonary vascular impairmentc 
No. 
43  








114  91  126  98  57% 23,3  12  – No cardiovascular, respiratory or 
pulmonary vascular impairment 
Abbreviations: VO2, oxygen uptake, pred, predicted; HR, heart rate; O2 pulse, oxygen consumed per heart rate; SpO2, arterial oxygen saturation; VE/MVV, ventilatory 
reserve; VE/VCO2, ventilatory equivalent for carbon dioxide; AT, anaerobic threshold; Vd/VT, dead-space fraction; p(A-a)O2, alveolar-arterial gradient; Y, yes; 
CTEPH, chronic thromboembolic pulmonary hypertension. 
a Peripheral oxygen saturation is mentioned given lack of arterial blood gases in the majority of patients. 
b Unresolved thrombi according to CTPA assessment and/or perfusion defects based on V/Q scan. 
c Patients with insufficient cardiopulmonary responses as determined by CPET despite the absence of objectified persistent vascular occlusions on CTPA and/or V/Q 
scan. 
Table 4 
Patient-reported outcome measures.  
Questionnairea Available 
records 
Median value before start of the 
rehabilitation program (IQR) 
Median value after completing the 






PEmb-QoL (range 0–27 
points)  
23 15 (12 to 17) 11 (8.7 to 13) −3.9 (−6.2 to 
−1.2)  
<0.001 15 (61) 
CIS (range 20–140 
points)  
18 93 (76 to 104) 67 (53 to 85) −16 (−39 to 
−3.5)  
0.003 N.A. 
HADS anxiety (range 
0–21 points)  
19 4.0 (2.0 to 7.0) 4.0 (1.0 to 6.0) −1.0 (−2.0 to 1.0)  0.189 1.6 (validated in 
COPD patients) (62) 
HADS depression (range 
0–21 points)  
19 6.0 (3.0 to 8.0) 4.0 (2.0 to 6.0) −1.0 (−2.0 to 1.0)  0.096 1.6 (validated in 
COPD patients) (62) 
Abbreviations: IQR, interquartile range; MCID, minimal clinically important difference; PEmb-QoL; PE-specific Quality of Life; CIS, Checklist Individual Strength- 
Fatigue; N.A., not available; HADS, Hospital Anxiety and Depression Scale. 
a Lower scores indicate better self-reported quality of life (PEmb-QoL), less fatigue (CIS), or a lower burden of anxiety/depression (HADS). 
b Wilcoxon signed rank test. 
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grade (3.7%). Importantly, while closely monitoring safety during the 
rehabilitation program, no thromboembolic or cardiac complications 
were observed besides one patient with new-onset atrial fibrillation. 
4. Discussion 
This study demonstrates that insufficient cardiopulmonary responses 
to exercise are common among patients who suffer from the PPES, which 
is not limited to patients with persistent vascular occlusions. Exercise 
limitation was consistent with pulmonary vascular and/or cardiovas-
cular impairment rather than respiratory impairment in all CTEPH pa-
tients, and also in more than half of non-CTEPH cases. A personalized 
12-week rehabilitation program in patients with PPES in whom 
CTEPH and CTEPD suitable for PEA or BPA were ruled out, appeared to 
improve the training intensity, the PE-specific quality of life as well as 
the burden of fatigue. Functional status in patients' daily lives improved 
as well during the rehabilitation program. During the program, one 
patient was diagnosed with new-onset with atrial fibrillation, no other 
complications occurred. 
Persistent thrombotic obstruction of pulmonary arteries was identi-
fied in about half of the non-CTEPH cases. However, increased dead- 
space ventilation or cardiovascular impairment was not observed in 
all of these patients. This illustrates the heterogeneous nature of physi-
ological etiologies explaining exertional dyspnea in this patient group. 
The lack of correlation between reduced exercise capacity and imaging 
abnormalities in our and previous studies further suggests a multifac-
torial etiology rather than vascular disease in pulmonary arteries as only 
physiological determinant of post-PE dyspnea [64]. This study was not 
designed to identify deconditioning since clear diagnostic criteria are 
lacking. Therefore, the prevalence of deconditioning may be under-
estimated, also because alternative reasons for exercise limitation might 
be predominant. An incremental symptom-limited CPET is the recom-
mended tool to comprehensively evaluate cardiovascular, ventilatory 
and peripheral metabolism responses in case of exertional dyspnea 
[51,52]. As such, non-invasive differentiation between mechanisms 



















PEmb-QoL before and after rehabilitation
Median before Median after
Fig. 2. Radar chart representing the change in all dimensions of the PEmb-Qol 
questionnaire before and after the rehabilitation program (N = 22); lower 
scores indicate better quality of life. 





PVFS scale grade Descripon
0 No funconal limitaons No symptoms, pain, or anxiety.
1 Negligible funconal limitaons All usual dues/acvies at home or at work can be carried out at the same level of 
intensity, despite some symptoms, pain, or anxiety.
2 Slight funconal limitaons Usual dues/acvies at home or at work are carried out at a lower level of 
intensity or are occasionally avoided due to symptoms, pain, or anxiety.
3 Moderate funconal limitaons Usual dues/acvies at home or at work have been structurally modified 
(reduced) due to symptoms, pain, or anxiety.
4 Severe funconal limitaons Assistance needed in acvies of daily living due to symptoms, pain, or anxiety: 
nursing care and aenon are required.
D Death -
Fig. 3. Assignments of the Post-VTE Functional Status (PVFS) scale grades before and after completing the 12-week pulmonary rehabilitation program (N = 27). 
Note: The width of lines in the figure are proportional to the flow rate. 
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cohort study, the majority (87.5%) of patients with an abnormal 12- 
month CPET after their first episode of PE had deconditioning, 12.5% 
were classified to have ventilatory impairment and none were consid-
ered to have cardiovascular impairment [19,20]. Of note, this was an 
unselected PE population with relatively low-risk PE patients. A recent 
observational study including 40 patients with PPES revealed increased 
dead-space ventilation and/or decreased stroke volume reserve in up to 
65% after 90 days of anticoagulant therapy [66]. Importantly, given the 
absence of unambiguous clinical algorithms for interpreting cardiopul-
monary responses to exercise, some phenotypes of exercise intolerance 
overlap. As such, CPET mainly functions as a first means of identifying 
patterns rather than making a clear distinction between different causes. 
Taking into account our results, we argue that rehabilitation is a safe and 
promising approach that is mainly valuable in a population of 
adequately selected PE patients suffering from persistent dyspnea. This 
is fueled by a recent randomized trial in which an 8-week home-based 
exercise program was initiated shortly after acute PE regardless of 
symptoms or pre-existing physical fitness [31]. Although this 
physiotherapist-guided program proved to be safe, the predefined 
criteria for efficacy have not been met. A currently ongoing randomized 
study evaluates whether a rehabilitation program improves exercise 
capacity in PPES patients (NCT03405480). Speculating, exercise 
training might also contribute to functional improvements in PPES pa-
tients treated with surgical, angioplasty or PH targeted therapy. Further 
randomized studies are needed to define criteria for adequate selection 
of particular PE patients who will likely benefit most from a rehabili-
tation program. 
Strengths of our study include the standardized diagnostic work-up 
in all patients including pulmonary perfusion imaging, CPET and 
echocardiography in all patients, as well as the application of a state-of- 
the art supervised rehabilitation program [42]. Limitations include its 
relatively small sample size, the single-center design and the likely se-
lection bias leading to an enriched CTEPH prevalence in the study 
population due to referral from elsewhere to our unique ‘post-PE syn-
drome clinic’. Therefore, the proportion of CTEPH versus CTEPD is 
probably not representative. Moreover, since pulmonary angiography 
was performed in case of suspected CTEPH only, i.e. in those patients 
with intermediate or high probability of CTEPH based on echocardiog-
raphy, we cannot state with complete certainty that none of the other 
patients with persistent perfusion defects actually had CTEPH. Also, the 
observational nature of our study without a control group hinders to 
reliably quantify the full effect of a rehabilitation program compared to 
standard recovery. Interestingly, most study patients also received other 
types of allied healthcare, which may have contributed to an improve-
ment in the functional status, a better quality of life and reduction in 
fatigue. However, previous prospective studies have shown limited 
improvement in the natural course of acute PE, especially when no 
rehabilitation program is offered. For example, a recent German cohort 
study following 620 PE patients showed that quality of life using the 
PEmb-QoL score improved between 3- and 12-month follow-up, but the 
MCID of 15 points was only attained in 118 patients (19%) [67]. Of note, 
this MCID was obtained in a small selected cohort of 82 patients, which 
may have limited its generalizability [61]. Lastly, limitations of the pre- 
post study design are known and includes the lack of clear causality of 
the intervention on the observed changes, also due to unexpected tem-
poral changes, regression to the mean, testing threat, and non-specific 
effects of the intervention. 
In summary, insufficient cardiopulmonary responses to exercise 
seem to play an important role in the etiology of exertional dyspnea and 
functional limitations after acute PE, and were independent of persistent 
perfusion defects in the studied cohort. Our data suggest that offering a 
personalized pulmonary rehabilitation program to patients with PPES 
not otherwise treated is safe and promising given the observed 
improvement in patient-relevant outcomes. Randomized studies are 
nonetheless required to validate our findings and to further determine 
which PPES patients benefit most from rehabilitation. 
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